Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 09, 2024

BUY
$0.11 - $0.22 $1,650 - $3,300
15,000 New
15,000 $1,000
Q2 2023

Jul 12, 2023

BUY
$1.25 - $1.92 $19,250 - $29,568
15,400 New
15,400 $19,000
Q4 2022

Jan 11, 2023

BUY
$1.2 - $1.83 $14,400 - $21,960
12,000 New
12,000 $0

Others Institutions Holding ARAV

About Aravive, Inc.


  • Ticker ARAV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,518,300
  • Description
  • Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of pl...
More about ARAV
Track This Portfolio

Track Collective Family Office LLC Portfolio

Follow Collective Family Office LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Collective Family Office LLC, based on Form 13F filings with the SEC.

News

Stay updated on Collective Family Office LLC with notifications on news.